<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537871</url>
  </required_header>
  <id_info>
    <org_study_id>19424</org_study_id>
    <secondary_id>NCI-2020-06749</secondary_id>
    <secondary_id>19424</secondary_id>
    <secondary_id>P30CA033572</secondary_id>
    <secondary_id>R01HL150069</secondary_id>
    <nct_id>NCT04537871</nct_id>
  </id_info>
  <brief_title>Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study</brief_title>
  <official_title>Cardiovascular Reserve Evaluation in Survivors of Transplantation (CREST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates how well the heart, lungs, and muscles are working individually, and how&#xD;
      these systems are working together in transplant survivors. Information collected in this&#xD;
      study may help doctors to understand why hematopoietic stem cell transplant survivors are at&#xD;
      higher risk for developing cardiovascular disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption&#xD;
      (VO2peak), in hematopoietic cell transplantation (HCT) survivors.&#xD;
&#xD;
      II. Define the determinants of VO2peak impairment in HCT survivors.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary&#xD;
      exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance&#xD;
      analysis to measure total lean body mass and percent body fat), physical function tests, and&#xD;
      collection of blood samples within 45 days from the start of conditioning therapy, and at 6&#xD;
      months, 1 year, and 2 years post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">September 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular reserve capacity, as measured by VO2peak, in HCT survivors</measure>
    <time_frame>Up to 24 months post-hematopoietic cell transplantation (HCT)</time_frame>
    <description>We will measure initial VO2peak in patients prior to HCT and its post-HCT trajectory over time; compare VO2peak in HCT survivors at baseline (pre-HCT), 6m, 1Y, and 2Y post-HCT to established age- and sex-normative data; and define the association between VO2peak and self-reported health-related quality of life (HRQOL) at baseline/over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determinants of VO2peak impairment in HCT survivors</measure>
    <time_frame>Up to 24 months post-hematopoietic cell transplantation (HCT)</time_frame>
    <description>We will use Generalized Estimating Equation(GEE) and generalized linear models to examine the correlation between VO2peak and measures of:&#xD;
cardiac (left ventricular function/ contractility [systolic, diastolic, cardiac output, strain], ventricular-arterial (VA) coupling, arterial elastance);&#xD;
pulmonary (obstructive, restrictive lung disease, diffusion capacity);&#xD;
musculoskeletal (body composition [% lean muscle mass], muscle quality, two minute step in place test, 30 second sit to stand test, timed up and go); and&#xD;
hematologic function, adjusting for potential confounding variables (e.g. age, sex) and time since HCT.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <condition>Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
    <description>Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bioelectric Impedance Analysis</intervention_name>
    <description>Undergo bioelectric impedance analysis</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
    <other_name>BIA</other_name>
    <other_name>Bioelectric Impedance</other_name>
    <other_name>Bioelectric Impedance Test</other_name>
    <other_name>Bioelectrical Impedance Analysis</other_name>
    <other_name>Bioimpedance Analysis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biospecimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiopulmonary Exercise Testing</intervention_name>
    <description>Undergo cardiopulmonary exercise test</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
    <other_name>CPET</other_name>
    <other_name>CPX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography</intervention_name>
    <description>Undergo echocardiogram</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Performance Testing</intervention_name>
    <description>Undergo physical function tests</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
    <other_name>Physical Fitness Testing</other_name>
    <other_name>Physical Function Testing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pulmonary Function Test</intervention_name>
    <description>Undergo pulmonary function test</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
    <other_name>lung function test</other_name>
    <other_name>PFT</other_name>
    <other_name>Pulmonary Function Testing</other_name>
    <other_name>Pulmonary Function Tests</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Undergo musculoskeletal ultrasound</description>
    <arm_group_label>Observational (physical assessment)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin), multiple&#xD;
        myeloma or myelodysplastic syndromes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at HCT &gt;= 18 years&#xD;
&#xD;
          -  Diagnosis of acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin),&#xD;
             multiple myeloma or myelodysplastic syndromes&#xD;
&#xD;
          -  Planning to undergo first autologous or allogeneic transplant&#xD;
&#xD;
          -  Able to fluently read and write in English&#xD;
&#xD;
          -  Able to understand and sign the study specific informed consent form (ICF)&#xD;
&#xD;
          -  Physically able and willing to complete all study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable bone lesions per electronic medical record review and/or notification from&#xD;
             patient's primary physician&#xD;
&#xD;
          -  Unstable angina or history of acute myocardial Infarction (&lt; 5 days of any planned&#xD;
             study procedures)&#xD;
&#xD;
          -  Recurrent syncope&#xD;
&#xD;
          -  Acute myocarditis or pericarditis&#xD;
&#xD;
          -  Symptomatic severe aortic stenosis&#xD;
&#xD;
          -  Uncontrolled arrhythmia causing symptoms&#xD;
&#xD;
          -  Pulmonary embolus &lt; 3 month of study procedures&#xD;
&#xD;
          -  Thrombosis of lower extremities&#xD;
&#xD;
          -  Moderate or severe persistent asthma (National Asthma Education &amp; Prevention)&#xD;
&#xD;
          -  Room air desaturation at rest =&lt; 85%&#xD;
&#xD;
          -  Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by&#xD;
             exercise (i.e. infection, renal failure, thyrotoxicosis)&#xD;
&#xD;
          -  Anemia (hemoglobin [Hgb] &lt; 8 g/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saro H Armenian</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saro H. Armenian</last_name>
      <phone>626-359-8111</phone>
      <email>SArmenian@coh.org</email>
    </contact>
    <investigator>
      <last_name>Saro H. Armenian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

